Revance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note issued to investors on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

RVNC has been the subject of several other research reports. Mizuho reduced their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research note on Tuesday, December 10th. HC Wainwright reiterated a “neutral” rating and set a $6.60 price target on shares of Revance Therapeutics in a research report on Friday, November 8th. Barclays lowered their price target on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a report on Friday, November 8th. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $8.39.

Revance Therapeutics Price Performance

RVNC opened at $3.09 on Friday. Revance Therapeutics has a 12 month low of $2.30 and a 12 month high of $8.98. The stock has a market capitalization of $322.57 million, a P/E ratio of -1.60 and a beta of 0.86. The business has a 50 day simple moving average of $3.91 and a 200-day simple moving average of $4.48.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $67.73 million. Research analysts anticipate that Revance Therapeutics will post -1.57 EPS for the current year.

Institutional Investors Weigh In On Revance Therapeutics

A number of large investors have recently bought and sold shares of RVNC. Alpine Associates Management Inc. purchased a new stake in shares of Revance Therapeutics in the third quarter valued at $21,605,000. Stonepine Capital Management LLC raised its stake in Revance Therapeutics by 41.7% in the 2nd quarter. Stonepine Capital Management LLC now owns 2,800,000 shares of the biopharmaceutical company’s stock valued at $7,196,000 after purchasing an additional 823,658 shares during the last quarter. State Street Corp lifted its holdings in Revance Therapeutics by 6.6% in the 3rd quarter. State Street Corp now owns 2,433,963 shares of the biopharmaceutical company’s stock valued at $12,632,000 after purchasing an additional 150,323 shares in the last quarter. LMR Partners LLP acquired a new stake in shares of Revance Therapeutics during the 3rd quarter worth about $11,648,000. Finally, Federated Hermes Inc. grew its holdings in shares of Revance Therapeutics by 43.0% during the second quarter. Federated Hermes Inc. now owns 2,237,505 shares of the biopharmaceutical company’s stock worth $5,750,000 after buying an additional 672,803 shares in the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.